Ozempic vs Wegovy: Same Medicine, Two Different Jobs

Yes — Ozempic and Wegovy contain the exact same active ingredient, semaglutide, and both are made by Novo Nordisk. Chemically, the medicine inside the pen is identical. What differs is how each is dosed, approved, and marketed. This is the single most important thing to understand, because it explains why two products that are molecularly the same can behave so differently in real life.

Semaglutide is a GLP-1 receptor agonist — it mimics the gut hormone GLP-1, which increases feelings of fullness, slows digestion, and improves blood sugar control. Those effects help with both diabetes and weight loss, which is why the same molecule earned two separate brand names for two separate uses.

Ozempic came first, approved in 2017 for type 2 diabetes. As trials revealed how much weight people lost, Novo Nordisk developed Wegovy, approved in 2021 specifically for chronic weight management. Same drug, deliberately packaged and dosed for different goals. A third product, Rybelsus, is oral semaglutide for diabetes — we cover swallowable options in [oral vs injectable GLP-1](/blog/oral-vs-injectable-glp1-which-is-right-for-you-2026).

The core differences are dose and FDA-approved use. Ozempic is approved for type 2 diabetes at maintenance doses of 0.5mg, 1.0mg, or 2.0mg weekly. Wegovy is approved for chronic weight management in adults and adolescents who meet BMI criteria, and it titrates up to a higher 2.4mg weekly dose — the dose studied in the major weight-loss trials.

That higher ceiling matters. The STEP 1 trial (NEJM 2021) tested semaglutide 2.4mg — Wegovy's dose — and found an average weight loss of about 14.9% over 68 weeks. Ozempic's diabetes trials used lower doses and reported smaller average weight loss, partly because the maximum dose is lower and partly because the study populations differed.

Wegovy also carries an extra approval Ozempic does not: in 2024, following the SELECT trial, the FDA approved Wegovy to reduce the risk of cardiovascular events (heart attack, stroke, cardiovascular death) in adults with heart disease and overweight or obesity. We break down that landmark study in [what the SELECT trial found](/blog/glp1-heart-health-what-the-select-trial-found). So while the molecule is shared, only Wegovy holds the weight-management and cardiovascular indications at the 2.4mg dose.

For weight loss specifically, Wegovy is the on-label choice, because it is the version FDA-approved for chronic weight management and studied at the 2.4mg dose that produced the strongest results. If your goal is weight management and you do not have diabetes, Wegovy is the product designed for that purpose.

That said, doctors sometimes prescribe Ozempic off-label for weight loss, particularly when Wegovy is in short supply or not covered by insurance. "Off-label" means using an approved drug for a purpose it is not officially approved for — a legal and common practice, but one that can affect insurance coverage. Because Ozempic tops out at 2.0mg rather than 2.4mg, the maximum dose is slightly lower.

Your diagnosis often makes the decision for you. If you have type 2 diabetes, Ozempic is typically the covered, on-label path and delivers both blood sugar control and weight benefits. If you are pursuing weight management without diabetes, Wegovy is the intended product. Either way, the choice is best made with your provider, who weighs your health history, goals, insurance, and current supply. If you are also comparing semaglutide to tirzepatide, see [tirzepatide vs semaglutide](/blog/tirzepatide-vs-semaglutide-which-works-better-2026) and [Wegovy vs Zepbound](/blog/wegovy-vs-zepbound-which-wins-for-weight-loss-2026).

Because they are the same molecule, the side effect profiles are essentially identical — the type of side effects does not change between Ozempic and Wegovy. Both most commonly cause gastrointestinal effects: nausea, vomiting, diarrhea, constipation, and reduced appetite, especially in the first weeks and after each dose increase.

The main practical difference is that Wegovy reaches a higher dose (2.4mg), and side effects with GLP-1s are partly dose-related. Some people notice slightly more intense GI effects at the top Wegovy dose than at lower Ozempic doses, though this varies widely between individuals. Both products are titrated up slowly for exactly this reason — to give your body time to adjust and to minimize nausea.

Other considerations apply to both: a boxed warning about thyroid C-cell tumors (based on rodent studies), and rare risks of pancreatitis and gallbladder problems, the latter more common during rapid weight loss. We cover these across our guides on [GLP-1 and gallstones](/blog/glp1-gallbladder-gallstones-risk-symptoms-what-to-know) and [GLP-1 thyroid safety](/blog/glp1-thyroid-safety-cancer-risk-what-research-shows). Managing the common GI effects is the same for both drugs: smaller, low-fat meals, hydration, and slow dose increases. For midlife women juggling menopause too, our guide on [managing side effects while in menopause](/blog/hot-flashes-and-nausea-managing-both-on-glp1-in-menopause) may help.

Cost and coverage differ mainly because insurance ties reimbursement to your diagnosis, not to the molecule. Many insurance plans cover semaglutide for type 2 diabetes (Ozempic) far more readily than for weight management (Wegovy), which some plans exclude entirely or cover only with prior authorization. This is why two people taking the same drug can pay wildly different amounts.

Both carry high list prices — often over a thousand dollars a month without coverage — but what you actually pay depends on your plan, deductible, and any manufacturer savings program. Novo Nordisk offers savings cards for eligible commercially insured patients, and cash-pay options have emerged. Coverage for weight-loss drugs specifically remains patchy: Medicare historically has not covered drugs used solely for weight loss, though Wegovy's cardiovascular approval opened a narrow path for some patients with heart disease.

Because this landscape shifts constantly, it pays to check your specific plan and explore every avenue. Our detailed guides can help: [how to get GLP-1 cheaper](/blog/how-to-get-glp1-cheaper-savings-cards-telehealth-2026), [does Medicare cover GLP-1](/blog/does-medicare-cover-glp1-weight-loss-2026-bridge-program), and [using FSA/HSA dollars](/blog/glp1-fsa-hsa-pre-tax-dollars-save-on-weight-loss-2026). The takeaway: the drug may be the same, but your out-of-pocket cost is driven by diagnosis, plan design, and paperwork.

Not sure which version fits your situation and budget? Lea can help you sort through it before your next appointment.